Membership and Financial Health

Together, we make IT happen.

The Society for Immunotherapy of Cancer (SITC) is the world’s only member-driven society dedicated to professionals working in the field of cancer immunotherapy. SITC members dedicate their time and talent to advance science, discover breakthroughs and educate the world on cancer immunotherapy. In short: to make the word “CURE” a reality for cancer patients everywhere. 

Membership

"SITC has given me a whole different level of understanding on what science and research is being done across the country and who is doing it." Jillian Hunt, MSN, APRN, FNP-C, AOCNP

Join or Renew Your SITC Membership

By the Numbers

4,467
total members
5%
INCREASE IN STUDENT MEMBERS
60%
HAVE BEEN MEMBERS FOR TWO YEARS OR LONGER

International Growth

Cancer remains one of the leading causes of death worldwide. By eliminating barriers to access, SITC has significantly expanded membership and participation across new regions around the globe. Further, to support the global immunotherapy community, SITC is committed to providing free annual membership and access to educational resources to those residing in low- and lower-middle-income economies (LMIEs). To learn more about SITC’s global efforts, click here.

88 countries were represented by SITC members in 2024 vs. 73 countries in 2023.

Volunteerism

Volunteers shape the direction of SITC’s strategic initiatives which in turn directly influence the immunotherapy field. Together, SITC volunteers are leading the field, elevating cancer immunotherapy as a standard of care. To chart the future, consider volunteering with SITC.


2,735
Volunteers
504
Committee Members
26
Committees
16
Cancer Immunotherapy Guidelines Expert Panels
2
Task Forces

Corporate Membership

SITC corporate memberships provide organizations vested in cancer immunotherapy and cancer research a forum to address common issues impacting the field with the goal of improving cancer patient outcomes. In 2024, SITC corporate members gathered with leaders from SITC and the FDA to discuss Project Optimus and accelerated approval for metastatic disease and connecting these mechanisms to potential use for cellular therapies and relevant endpoints such as objective response rate, progression free survival, and (landmark) overall survival. Additionally, the group discussed perioperative disease and its relevancy to endpoints such as pathologic complete response and circulating tumor DNA.

Corporate Council Members

Janssen

Corporate Members

Molecular Partners

Mural Oncology

To join the discussion and become a corporate member, visit: sitcancer.org/corporate-membership

Financial Health

SITC remains financially strong, with just under $25M in unrestricted net assets. This equates to almost two years worth of operating expenses. Operating income in 2024 was about $12.5M and operating expenses totaled $13.8M, which results in an operating net loss of just over $1.3M. Fortunately, SITC’s investment income is projected to make up about $800K of the operating net loss.